Why the study?
Does normokalemic cardioplegia (ALM) improve cardioprotection and outcomes compared to high K(+) cardioplegia in adult and pediatric cardiac surgery patients?
Does normokalemic cardioplegia (ALM) improve cardioprotection and outcomes compared to high K(+) cardioplegia in adult and pediatric cardiac surgery patients?
This review highlights the potential adverse effects of traditional high-potassium cardioplegia and proposes a novel normokalemic adenosine-lidocaine-magnesium (ALM) solution for improved cardioprotection in modern, higher-risk cardiac surgery patients.
Answers are grounded in this paper and cite their sources.
Supports randomized trials of ALM cardioplegia in cardiac surgery; leaves open superiority over high K+ solutions.
Despite surgical proficiency and innovation driving low mortality rates in cardiac surgery, the disease severity, comorbidity rate, and operative procedural difficulty have increased. Today's cardiac surgery patient is older, has a "sicker" heart and often presents with multiple comorbidities; a scenario that was relatively rare 20 years ago. The global challenge has been to find new ways to make surgery safer for the patient and more predictable for the surgeon. A confounding factor that may influence clinical outcome is high K(+) cardioplegia. For over 40 years, potassium depolarization has been linked to transmembrane ionic imbalances, arrhythmias and conduction disturbances, vasoconstriction, coronary spasm, contractile stunning, and low output syndrome. Other than inducing rapid electrochemical arrest, high K(+) cardioplegia offers little or no inherent protection to adult or pediatric patients. This review provides a brief history of high K(+) cardioplegia, five areas of increasing concern with prolonged membrane K(+) depolarization, and the basic science and clinical data underpinning a new normokalemic, "polarizing" cardioplegia comprising adenosine and lidocaine (AL) with magnesium (Mg(2+)) (ALM™). We argue that improved cardioprotection, better outcomes, faster recoveries and lower healthcare costs are achievable and, despite the early predictions from the stent industry and cardiology, the "cath lab" may not be the place where the new wave of high-risk morbid patients are best served.
No takes yet. Share an insight, caveat, or question.
Dobson et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: